SNDX - Syndax Pharmaceuticals Inc

QQQ $ 455.25 $ 5.77 (1.29 %)

DIA $ 409.08 $ 4.58 (1.13 %)

SPY $ 546.60 $ 6.05 (1.12 %)

TLT $ 99.96 $ 0.43 (0.43 %)

GLD $ 231.58 $ 0.97 (0.42 %)

Previous Close

$ 18.8

Open

Bid

$ 18.78 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 11.22 - $ 25.34

Volume

929,632

Average Volume

Market Cap

1.6B

Beta (5Y Monthly)

$ 0.77

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-01-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-02-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-08-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-15-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-11-2021	03-31-2021	10-Q
15	03-12-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	03-05-2020	12-31-2019	10-K
20	11-07-2019	09-30-2019	10-Q
21	08-07-2019	06-30-2019	10-Q
22	05-08-2019	03-31-2019	10-Q
23	03-07-2019	12-31-2018	10-K
24	11-05-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-08-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-10-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	03-14-2017	12-31-2016	10-K
32	11-14-2016	09-30-2016	10-Q
33	08-15-2016	06-30-2016	10-Q
34	05-16-2016	03-31-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Syndax Pharmaceuticals Partnered With Foun...
09/04/2024 11:12:41

Citigroup Maintains Buy on Syndax Pharmace...
08/16/2024 13:01:52

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target fr...

HC Wainwright & Co. Maintains Buy on Synda...
08/15/2024 17:26:30

HC Wainwright & Co. analyst Edward White maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price ...

B of A Securities Maintains Buy on Syndax ...
08/15/2024 17:22:54

B of A Securities analyst Jason Zemansky maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price targ...

fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-complication

FDA Approves Incyte/Syndax Partnered Drug ...
08/15/2024 14:11:20

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at...

Barclays Maintains Overweight on Syndax Ph...
08/15/2024 13:57:21

Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target f...

Incyte, Syndax Secure FDA Approval For Nik...
08/14/2024 21:55:48

FDA has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (G...

$syndax-pharmaceuticals-announced-that-data-from-phase-2-portion-of-the-augment-101-trial-of-revumenib-in-adult-and-pediatric-patients-with-relapsedrefractory-kmt2a-rearranged-acute-myeloid-leukemia-and-acute-lymphoid-leukemia-have-been-published-in-the-journal-of-clinical-oncology$

Syndax Pharmaceuticals Announced That Data...
08/12/2024 11:09:10

JP Morgan Maintains Overweight on Syndax P...
08/06/2024 16:25:14

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target f...

HC Wainwright & Co. Reiterates Buy on Synd...
08/02/2024 12:04:57

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

Syndax Pharmaceuticals Q2 2024 GAAP EPS $(...
08/01/2024 20:36:03

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate o...

HC Wainwright & Co. Reiterates Buy on Synd...
07/29/2024 17:45:42

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

FDA Extends Review Period for Syndax Pharm...
07/29/2024 11:03:07

Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer th...

Jefferies Initiates Coverage On Syndax Pha...
06/28/2024 12:49:09

Jefferies analyst Kelly Shi initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price...

Stifel Maintains Buy on Syndax Pharmaceuti...
06/26/2024 14:07:41

Stifel analyst Bradley Canino maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $40...

HC Wainwright & Co. Reiterates Buy on Synd...
06/17/2024 10:34:40

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

Syndax Pharmaceuticals Discloses Updated D...
06/14/2024 11:09:01

- Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of 24 pts) obs...

HC Wainwright & Co. Reiterates Buy on Synd...
06/06/2024 14:12:27

HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 pr...

Syndax's Revumenib To Enter Phase 1b For M...
06/06/2024 11:08:18

why-ooma-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-premarket

Why Ooma Shares Are Trading Higher By Arou...
05/29/2024 12:07:38